# A Phase III Confirmatory Study of K-237

> **NCT05056883** · PHASE3 · COMPLETED · sponsor: **Kowa Company, Ltd.** · enrollment: 1030 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** K-237 0.3-0.4mg/kg (once daily)
- **DRUG:** Placebo 0.3-0.4mg/kg (once daily)

## Key facts

- **NCT ID:** NCT05056883
- **Lead sponsor:** Kowa Company, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-22
- **Primary completion:** 2022-08-26
- **Final completion:** 2022-08-26
- **Target enrollment:** 1030 (ACTUAL)
- **Last updated:** 2024-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05056883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05056883, "A Phase III Confirmatory Study of K-237". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05056883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*